T 1868/16 (Everolsimus/NOVARTIS) of 08.11.2017
- European Case Law Identifier
- ECLI:EP:BA:2017:T186816.20171108
- Date of decision
- 8 November 2017
- Case number
- T 1868/16
- Petition for review of
- -
- Application number
- 10175197.2
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- mTOR inhibitors in the treatment of endocrine tumors
- Applicant name
- Novartis AG
- Opponent name
- Teva Pharmaceutical Industries Ltd.
Synthon B.V./Genthon B.V.
Ethypharm
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Generics [UK] Limited (trading as Mylan) - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)
- Keywords
- Sufficiency of disclosure - main request (no)
Auxiliary requests submitted with reply to the statment of grounds of appeal - admitted (yes)
Late filed auxiliary request 6 - admitted (no)
Sufficeincy of disclosure - auxiliary requests (no) - Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.